Matt Taylor

could you comment on what you think the impact could be from the CHAMPION study from your competitor?

What's the outlook like for diagnostics in China

I just wanted to know better what you were assuming for the Novum returns, just so we can understand if there aren't returns, what the upside could be?

if it stays elevated, is it still manageable in 2027? Or can you provide any framing of exposure there next year

I'd love to hear from you what you think could happen, what could go right near term with some of these immediate actions you're taking and maybe qualitatively describe the range of possibilities o...

previously you had talked about the potential for the GLP-1 franchise within Becton, Dickinson and Company to get to about $1 billion by the end of the decade

I was hoping that you could delve into some of the different levers that you can pull and when you might look to pull them

maybe just talk about the trend in China and some of the headwinds that you've been seeing

now that you've closed APM, if you could give us some additional thoughts on how you think that segment could grow over time

for more clarity on WATCHMAN in terms of how stand-alone was growing. You mentioned it was decelerating

do you think there's any chance of showing superiority on any of the endpoints or the secondary endpoints?

Your competitor said they are not going to call the month, basically implying it could happen soon. I know you do not know exactly when it is going to happen, but what are your thoughts on whether ...

I wanted to have you talk a little bit more about where the existing legacy and core markets could go in the coming years, but also with an eye to non intensive type two coverage

Could you talk about the potential to get broader NIT2 coverage earlier in '26? And what would be the mechanism to do that

I wanted to just ask if you could give us an update on how things are going with the FDA and the progress that you've been making in the plants that were inspected

did supply have any impact on the revenue growth? Could you characterize that? And then you keep talking about the gap closing between dollars and volumes

when do you think you'll actually get more of an uptake in that non-insulin type two population

There's been some chatter about concerns with changes in the macro environment and coverage.

are you assuming any increase in your competitive position or share gains?

I wanted to dig into the better performance we've seen in TAVR especially in The U.S. the last couple of quarters and just ask you what you thought was causing that

after this tricuspid data and having the toolbox there. Do you expect some acceleration in the tricuspid adoption could we also see that in mitral next year

would you venture a guess that what proportion of the Boston Scientific exited sales you could get? What's kind of your fair share of that

I just wanted to confirm that none of the guidance range was really around M3

I was wondering if you could give us any framework or guidepost to help us understand how much growth is coming from those different sources

could you help us understand what the gating factors are there to drive more production

So just wanted to get more color on the current state of supply, how things are going with the big partners that you signed

I did want to ask first for a little bit more color about the 2% order growth

updated views on organic and especially inorganic investments

highlight some of the key products that you're expecting to launch and the kind of impact that we could expect from them

talk about the gating factors and how you expect reimbursement to evolve and then the steps through actually getting on contract

help us a little bit more with any segment color in terms of the growth expectations for 2025

I was wondering if you could comment about why you didn't just buy the whole company versus invest? And we also saw over the weekend, the results of a longer-term follow-up for CoreValve published ...

if you could expand on some of the pipeline ideas that you had for diabetes and about their differentiation and timelines

Do you expect that launch, I guess, to drive just increased share gains and customer starts? Or could you actually get price mix benefits from the launch of Omnipod 6 as well

Do you think that we’ll continue to see that kind of growth towards the Dexcom number over time? Or are you viewing your growth in the future coming more from “same-store growth”

Could you help us understand how much of a tail end it is now or it could be in the future?

Maybe you could just summarize in your words, the impact that it did have on your business and maybe more importantly, didn't have

have you had any discussions or back and forth with folks in the government about broader exemptions for med tech

if we woke up tomorrow and the tariffs were gone, maybe theoretically had this $200 million back or some function of that

what are you assuming for the rest of the year with regards to EPA tariffs or tariffs in general

was hoping that you could go through all the the puts and takes on gross margin this year

would you expect some pickup in those areas that you saw softness in Q3 in 2026 just at a high level

if you could give us about what the headwind would have been without mitigation